StreetInsider.com News Articles

Form ARS OS Therapies Inc For: Dec 31

Fri, 24 Jul 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260724/26813974.html

Form ARS OS Therapies Inc For: Dec 31

Fri, 24 Jul 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260724/26813974.html

Form DEFA14A OS Therapies Inc

Fri, 24 Jul 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260724/26813937.html

Form DEFA14A OS Therapies Inc

Fri, 24 Jul 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260724/26813937.html

Form DEF 14A OS Therapies Inc For: Sep 09

Fri, 24 Jul 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260724/26813736.html

Form DEF 14A OS Therapies Inc For: Sep 09

Fri, 24 Jul 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260724/26813736.html

Form 3 OS Therapies Inc For: Jul 01 Filed by: EAGLE CRAIG

Thu, 23 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260723/26808292.html

Form 3 OS Therapies Inc For: Jul 01 Filed by: EAGLE CRAIG

Thu, 23 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260723/26808292.html

Form D OS Therapies Inc

Thu, 16 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260716/26775935.html

Form D OS Therapies Inc

Thu, 16 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260716/26775935.html

Roth/MKM Starts OS Therapies, Inc (OSTX) at Buy, PT $7, 'Durable Survival Supports OST-HER2 Approval'

Thu, 09 Jul 2026 09:37:02 -0400

(Updated - July 9, 2026 9:37 AM EDT)

Roth/MKM analyst Adam Walsh initiates coverage on OS Therapies, Inc (NYSE: OSTX) with a Buy rating and a price target of $7.00.

The analyst comments "Initiating Buy, $7 target. We believe OST-HER2 works and approval is more a question of timing. The Listeria immunotherapy achieved 75% 2.5-year overall survival (OS) versus 47% for a pooled historical control (p=0.003) in recurrent, fully resected, pulmonary metastatic osteosarcoma. Milestones are FDA alignment on the endpoint and comparator, and the three-year OS update in early fall 2026. We expect US accelerated approval (70% POA) in late 4Q26 followed

Roth/MKM Starts OS Therapies, Inc (OSTX) at Buy, PT $7, 'Durable Survival Supports OST-HER2 Approval'

Thu, 09 Jul 2026 09:37:02 -0400

(Updated - July 9, 2026 9:37 AM EDT)

Roth/MKM analyst Adam Walsh initiates coverage on OS Therapies, Inc (NYSE: OSTX) with a Buy rating and a price target of $7.00.

Roth/MKM Starts OS Therapies, Inc (OSTX) at Buy, PT $7, 'Durable Survival Supports OST-HER2 Approval'

Thu, 09 Jul 2026 09:37:02 -0400

(Updated - July 9, 2026 9:37 AM EDT)

Roth/MKM analyst Adam Walsh initiates coverage on OS Therapies, Inc (NYSE: OSTX) with a Buy rating and a price target of $7.00.

Roth/MKM Starts OS Therapies, Inc (OSTX) at Buy, PT $7, 'Durable Survival Supports OST-HER2 Approval'

Thu, 09 Jul 2026 09:37:02 -0400

(Updated - July 9, 2026 9:37 AM EDT)

Roth/MKM analyst Adam Walsh initiates coverage on OS Therapies, Inc (NYSE: OSTX) with a Buy rating and a price target of $7.00.

Form 8-K/A OS Therapies Inc For: Jun 30

Tue, 07 Jul 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260707/26739818.html

Form 8-K/A OS Therapies Inc For: Jun 30

Tue, 07 Jul 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260707/26739818.html

Form 8-K OS Therapies Inc For: Jun 30

Thu, 02 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260702/26728410.html

Form 8-K OS Therapies Inc For: Jun 30

Thu, 02 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260702/26728410.html

OS Therapies to report significant survival benefit for OST-HER2 in osteosarcoma

Tue, 02 Jun 2026 06:09:35 -0400

Investing.com -- OS Therapies is expected to report today that its lead immunotherapy candidate, OST-HER2, has achieved a statistically significant overall survival benefit at 2.5 years in patients with fully resected pulmonary metastatic osteosarcoma, Investing.com has learned.

The data is expected to strengthen the company's push for early market authorizations across major regulatory jurisdictions.

According to information seen by Investing.com, patients treated with OST-HER2 achieved a 75% overall survival rate at 2.5 years.

No new patient deaths were reported in the treated group between the previously reported two-year analysis and the latest 2.5-year data cut.

The updated results build on earlier

OS Therapies, Inc (OSTX) PT Lowered to $13 at Lake Street

Tue, 19 May 2026 08:56:35 -0400

Lake Street analyst Chad Messar lowered the price target on OS Therapies, Inc (NYSE: OSTX) to $13.00 (from $14.00) while maintaining a Buy rating.

OS Therapies Incorporated (OSTX) Reports Q1 Loss of $0.27

Mon, 18 May 2026 16:46:21 -0400

OS Therapies Incorporated (NYSE: OSTX) reported Q1 EPS of ($0.27).

For earnings history and earnings-related data on OS Therapies Incorporated (OSTX) click here.

Form 10-Q OS Therapies Inc For: Mar 31

Mon, 18 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260518/26509702.html

Form 10-Q OS Therapies Inc For: Mar 31

Mon, 18 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260518/26509702.html

Form 5/A OS Therapies Inc For: Dec 31 Filed by: Romness Paul A.

Fri, 15 May 2026 18:30:00 -0400

si-local-file:///var/storage/secattach/20260515/26508256.html

Form 5/A OS Therapies Inc For: Dec 31 Filed by: Romness Paul A.

Fri, 15 May 2026 18:30:00 -0400

si-local-file:///var/storage/secattach/20260515/26508256.html